Clinical trials
Bladder (Urothelial, Transitional Cell) Cancer clinical trials
Below are recruiting bladder (urothelial, transitional cell) cancer clinical trials, each written for real people, not researchers. We’re tracking 34 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07646145RecruitingPhase 2
Disitamab Vedotin Plus Mitomycin C for HER2-Positive Bladder Cancer
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
Taiyuan, ShanxiAges 18 years+ - NCT03945162RecruitingPhase 2
Bladder cancer trial using light therapy in the bladder
This Phase 2 study tests a treatment called photodynamic therapy (PDT) placed directly into the bladder. It may help people whose non–muscle-invasive bladder cancer did not respond to BCG treatment or could not tolerate it.
Chicago, IllinoisAges 18 years+ - NCT06257017RecruitingPhase 2
Using DNA tests to guide chemotherapy after bladder cancer surgery
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
Hong Kong, Hong KongAges 18–70 - NCT07468851RecruitingPhase 1/Phase 2
Study of HS-10566 for high-risk bladder cancer that hasn't spread into muscle
This study tests a new treatment called HS-10566 for people with a type of bladder cancer that has not reached the muscle layer and is considered high-risk, where the usual treatments have not worked or were not an option. It aims to control the cancer and avoid the need for removing the bladder.
BeijingAges 18 years+ - NCT06862219RecruitingPhase 4
Enfortumab Vedotin safety study for advanced urothelial cancer
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
Patna, BiharAges 18 years+ - NCT07353294Enrolling by invitationPhase 1
Propranolol plus immunotherapy and chemo before bladder cancer surgery
This trial tests adding a blood pressure medication (propranolol) to a combination of immunotherapy (tislelizumab) and chemotherapy before surgery for bladder cancer that has spread to lymph nodes. It aims to see if this can help shrink the tumor before it is removed.
Guangzhou, GuangdongAges 18 years+ - NCT06529822RecruitingPhase 1
Personalized cancer vaccine for solid tumors with residual disease
This trial tests a personalized cancer vaccine designed to help your immune system fight any remaining cancer cells after surgery. It is for people with certain solid tumors—like bladder, stomach, melanoma, or lung cancer—that show signs of disease through a blood test.
Orlando, FloridaAges 18 years+ - NCT06388720RecruitingPhase 2
Two chemotherapy drugs for bladder cancer after BCG
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Goyang-siAges 20 years+ - NCT06186414RecruitingPhase 1
SIM0237 with or without BCG for bladder cancer
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06972615RecruitingPhase 2
Bladder chemo plus pembrolizumab for BCG-treated cancer
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
CABAAges 18 years+
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bladder (urothelial, transitional cell) cancer?
- Yes. Clin2 currently lists 34 recruiting bladder (urothelial, transitional cell) cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bladder (urothelial, transitional cell) cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bladder (urothelial, transitional cell) cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.